Dissimilar patterns of tumor-infiltrating immune cells at the invasive tumor front and tumor center are associated with response to neoadjuvant chemotherapy in primary breast cancer
Dissimilar patterns of tumor-infiltrating immune cells at the invasive tumor front and tumor center are associated with response to neoadjuvant chemotherapy in primary breast cancer
复制标题
DOI：
10.1186/s12885-019-5320-2
复制
发表时间：
2019-02-04
期刊：
影响因子：
3.8
通讯作者：
Bankfalvi, Agnes
中科院分区：
文献类型：
--
作者：
Koenig, Lisa;Mairinger, Fabian D.;Bankfalvi, Agnes
肿瘤浸润性淋巴细胞(TIL)被认为是肿瘤微环境中重要的免疫调节因子，与乳腺癌(BC)的预后有关。TIL和TIL亚型在侵袭性肿瘤前沿(ITF)和肿瘤中心(TC)的空间分布可能为进一步了解肿瘤的进展提供依据。方法分析87例治疗前BC患者核心活检组织中总TIL和CD3+、CD4+、CD8+、CD20+和CD68+细胞与临床病理参数和骨髓中播散性肿瘤细胞(DTC)的相关性。TIL，尤其是CD3+T细胞与肿瘤状态和肿瘤分级有关。对新辅助化疗有反应的BC患者在TC处TIL和CD3+T细胞显著增加。结论TIL和TIL亚型与临床病理参数、NACT反应和微小残留病的空间相关性不同，提示有必要对TIL进行详细的分析，以更好地了解免疫调节过程。
BackgroundTumor-infiltrating lymphocytes (TILs) are described as an important immune modulator in the tumor microenvironment and are associated with breast cancer (BC) outcome. The spatial analysis of TILs and TIL subtype distribution at the invasive tumor front (ITF) and the tumor center (TC) might provide further insights into tumor progression.MethodsWe analyzed core biopsies from 87 pre-therapeutic BC patients for total TILs and the following subtypes: CD3+, CD4+, CD8+, CD20+ and CD68+ cells in correlation to clinicopathological parameters and disseminated tumor cells (DTCs) in the bone marrow.ResultsTILs and TIL subtypes showed significantly different spatial distribution among both tumor areas. TILs, especially CD3+ T cells were associated with the tumor status and tumor grading. BC patients responding to neoadjuvant chemotherapy had significantly more TILs and CD3+ T cells at the TC. The presence of DTCs after NACT was related to CD4+ infiltration at the TC.ConclusionThe dissimilar spatial association of TILs and TIL subtypes with clinicopathological parameters, NACT response and minimal residual disease underlines the necessity of detailed TIL analysis for a better understanding of immune modulatory processes.